LDS/Medical Tests/Integrin Subunit Beta 3 (ITGB3) Gene Mutation Analysis

Integrin Subunit Beta 3 (ITGB3) Gene Mutation Analysis

Integrin receptors are composed of two alpha, and two beta chains. These transmembrane receptors are present in many different kinds of cells and are involved in a variety of signaling pathways. Integrin Subunit beta 3 (ITGB3) is the beta 3 subunit of the integrin protein and is coded by the ITGB3 gene at 17q21.32. ITGB3 together with ITGB2B forms a receptor (also known as alpha IIb/beta 3) that is abundantly expressed on platelets and megakaryocytes. It has a high affinity for fibrinogen, and to a lesser extent fibronectin, prothrombin, thrombospondin, plasminogen, von Willebrand factor, and vitronectin. In activated platelets, plasma fibrinogen binds to alpha IIb/beta 3 and allows platelet-to-platelet crosslinking or aggregation and endothelial adherence. A polymorphism in the ITGB3 gene coding for the GBIIIa glycoprotein (176T>C, rs5918) results in a substitution of leucine to proline at position 59 of the GBIIIa subunit which is associated with increased platelet reactivity.

Mutations of the ITGB3 gene may result in a deficiency or poor functioning of alpha IIb/beta 3 which may result in a bleeding diathesis. Over 130 such mutations are associated with Glanzmann thrombasthenia, also known as hereditary familial thrombocytopenia, an autosomal recessive condition where both genes are mutated leading to a deficiency of alpha IIb/beta 3 on the platelet surface. This results in diminished fibrinogen binding to platelets, poor platelet-to-platelet interaction and impaired platelet plug formation. Most patients have a history of bruising as a neonate and mucocutaneous bleeding. If only one copy of the gene is mutated, it may result in a less severe condition, platelet type bleeding disorder 16. In this disorder overactive alpha IIb/beta 3 on platelets excessively binds to fibrinogen resulting in platelet removal in the spleen and thrombocytopenia which can result in a mild bleeding tendency.

Recent studies have reported that the platelet 176T>C polymorphism of GPIIIa may induce a hypercoagulable state through platelet hyperreactivity. This procoagulant effect may confer resistance to the antithrombotic effects of low-dose aspirin. However, because the variability in response to antiplatelet drugs is multifactorial and not caused only by single gene mutations, testing for the ITGB3 mutation alone cannot be used as a diagnostic tool.

  • As an aid in the diagnosis of Glanzmann thrombasthenia (hereditary familial thrombocytopenia)
  • Evaluate platelet function and activity in response to therapeutic drugs

A positive result indicates the presence of germline mutations in the ITGB3 gene thus confirming Glanzmann thrombasthenia.

A negative result indicates the absence of germline mutations in the ITGB3 but due to genetic heterogeneity it does completely not rule out Glanzmann thrombasthenia and other genes should be examined e.g. ITGA2B.

176T>C mutation of ITGB3 is 176 TT. This is consistent with Normal platelet reactivity

Real-time Polymerase Chain Reaction (PCR), Targeted sequence polymerase chain reaction (PCR), next-generation sequencing (NGS), Sanger sequencing.

Whole blood, Lavender-top (EDTA) or yellow-top (ACD) tube, buccal swab, saliva.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 8 days (preferred)
  • Frozen: 30 days
CD61 flow-cytometric analysis, CBC, platelet count, bleeding time, platelet function analyzer -100 (PFA-100), platelet aggregation, and adhesion studies, ristocetin induced aggregation test, fibrinogen assay, liver function tests, von Willebrand factor assay, d-dimer.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login